



2020 Post-SITC Conference

Next Steps in Cancer Immunotherapy

3/21-22 Sat. & Sun. @桃園機捷 A8 福容大飯店

3/21 Saturday

Time	Min'	Topic		
12:20-12:50	30	Lunch (members only) / TSITC Members Assembly & Honorary Member Award		
Time	Min'	Topic	Speaker	Moderator
13:00-13:15	15	Day 1 Opening	張文震理事長 台灣免疫暨腫瘤學會	
Virus Driven Cancers				
13:15-13:35	20	Merkel Cell Carcinoma (MCC): Viral Antigen as Tumor Rejection Antigens	王研人醫師 馬偕醫院皮膚科	張義芳主任 馬偕醫院癌症中心
		Final Results from a Phase 2 Study Using Off-the-shelf Activated Natural Killer (aNK) Cells in Combination with N-803, an IL-15 Superagonist, in Patients with Metastatic Merkel Cell Carcinoma		
		13:35-13:45		
13:45-14:00	15	EBV and Cancers	陳榮隆醫師 和信治癌中心醫院 小兒血液腫瘤科	江東和部主任 林口長庚兒童內科
14:00-14:05	05	Discussion		
14:05-14:20	15	HPV and Head and Neck Cancers	連銘渝醫師 中國附醫血液腫瘤科	楊慕華副校長 陽明大學 臺北榮總腫瘤醫學部
14:20-14:25	05	Discussion		
14:25~14:45	20	Break		
Special Lecture				
14:45~15:25	40	Technology for Engineering Exosomes in Immunotherapy	Prof. James Lai (賴志遠教授) Department of Bioengineering University of Washington	Prof. Alex Chang (張元吉教授) Johns Hopkins Singapore
15:25~15:35	10	Discussion		



2020 Post-SITC Conference

Next Steps in Cancer Immunotherapy

3/21-22 Sat. & Sun. @桃園機捷 A8 福容大飯店

3/21 Saturday

Time	Min'	Topic	Speaker	Moderator
High Impact Clinical Trials in NSCLC				
15:35-16:05	30	IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC	周百謙主任 臺北醫學大學附醫 胸腔內科	張文震理事長 台灣免疫暨腫瘤學會
		A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis		
		Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors		
		Clinical response to tumor infiltrating lymphocytes (TIL) in stage 4 non-small cell lung cancer (NSCLC) correlates with neoantigen-specificity: A phase I trial		
16:05-16:15	10	Discussion		
Imaging Technologies				
16:15-16:35	20	ImmunoPET for Whole Body Imaging of Immune Cell Subsets	何宗穎醫師 林口長庚核子醫學部	鄭澄意副院長 三軍總醫院 核子醫學部
		Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT		
16:35-16:45	10	Discussion		
16:45-16:55	05	Day 1 Closing	張文震理事長 台灣免疫暨腫瘤學會	



2020 Post-SITC Conference

Next Steps in Cancer Immunotherapy

3/21-22 Sat. & Sun. @桃園機捷 A8 福容大飯店

3/22 Sunday

Time	Min'	Topic	Speaker	Moderator
09:30-09:35	05	Day 2 opening	張文震理事長 台灣免疫暨腫瘤學會	
NK Cells: From Basic Science to Clinical Application				
09:35-10:05	30	Harnessing Innate Immunity in Cancer	張順浪博士 基亞生物科技公司	徐祖安教授 國衛院生藥研究所
		Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape		
10:05-10:15	10	Discussion		
Autoimmunity, Toxicity, Clinical Management and Cancer Immunotherapy				
10:15-10:40	25	Clinical Considerations of Immune-Related Adverse Events	許秉寧教授 臺大醫學院免疫學研究所	劉俊煌主任 台北慈濟 癌症研究中心
		Management of Complex IO Toxicity		
		Immune checkpoint inhibitor therapy in patients with preexisting autoimmune disease		
10:40-10:45	05	Discussion	郭家榮醫師 林口長庚醫院胃腸科	
10:45-11:00	15	Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease		
11:00-11:05	05	Discussion		
11:05-11:25	20	Break		
Special Lecture				
11:25-11:50	25	Antigen-Specific Cancer Immunotherapy	陳三奇醫師 臺北榮總腫瘤醫學部	張文震理事長 台灣免疫暨腫瘤學會
11:50-12:00	10	Discussion		
12:00-12:50	50	Lunch		



2020 Post-SITC Conference

Next Steps in Cancer Immunotherapy

3/21-22 Sat. & Sun. @桃園機捷 A8 福容大飯店

3/22 Sunday

Time	Min'	Topic	Speaker	Moderator
A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors				
12:50-13:20	30	Neoadjuvant Immunotherapy for Glioblastoma	周德陽院長 中國附醫 神經外科部	魏國珍副部長 林口長庚腦腫瘤 神經外科
		Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma		
		Difference Between the Application of Adoptive Cellular Therapy for Primary versus Metastatic Tumors		
		Immunotherapy for CNS Metastatic Tumors		
13:20-13:30	10	Discussion		
Hot Topic: Modifiable Host Factors and Immune Response				
13:30-13:50	20	Impact of Obesity on Immunotherapy: Both the Good and the Bad	陳怡文醫師 林口長庚內分泌新陳代謝科	劉妙真醫師 林口長庚 內分泌新陳代謝科
		Diet and physical activity alter immunity and the tumor microenvironment		
13:50-13:55	05	Discussion		
National Cancer Institute Update				
13:55-14:15	20	Real-world Data of Cancer Immunotherapy in Taiwan	柯博升醫師 臺大醫院血液腫瘤科	王正旭醫師 基隆長庚血液腫瘤科
14:15-14:25	10	Discussion		
14:25-14:45	20	Break		



2020 Post-SITC Conference

Next Steps in Cancer Immunotherapy

3/21-22 Sat. & Sun. @桃園機捷 A8 福容大飯店

3/22 Sunday

Time	Min'	Topic	Speaker	Moderator
Combination Phase 1-2 Clinical Trials & Update on Combinations				
14:45-14:55	10	A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma	吳教恩醫師 林口長庚腫瘤科	顏厥全主任 臺北榮總 腫瘤免疫治療中心
14:55-15:05	10	Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study		
		Novel Combination: IL-2 Combination		
15:05-15:15	10	Discussion		
15:15-15:25	10	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216)	謝耀宇醫師 雙和醫院血液腫瘤科	
15:25-15:35	10	Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI)		
15:35-15:45	10	Discussion		
15:45-15:55	10	Day 2 Closing		

2020 Post-SITC Conference